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Abstract
Dolichols, polyisoprene alcohols derived from the mevalonate pathway of cholesterol synthesis,
serve as carriers of glycan precursors for the formation of oligosaccharides important in protein
glycosylation. Seven autosomal-recessively inherited disorders in the metabolism (synthesis,
utilization, recycling) of the dolichols have recently been described, and all are associated with
decreased lipid-linked oligosaccharides leading to underglycosylated proteins or lipids which
facilitate their detection in the diagnostic laboratory. Multisystem pathology encompasses
developmental delays and eye, heart, skin and muscle abnormalities; outcomes range from death
in infancy to mild, late-onset disease.
Keywords
ichthyosis; retinitis pigmentosa; muscular dystrophy; dolichol; glycosylation; mannosylation;
isoprene; isoprenoids; cholesterol
INTRODUCTION
With pleiotropic roles in cell structure, embryo development, and signaling it is not
surprising that the inherited disorders of cholesterol biosynthesis feature a prominent
component of malformation [Porter and Herman, 2011; Schaaf et al., 2011; Shackleton,
2012]. The majority of these disorders reside in the distal portion of the pathway (e.g.,
beyond farnesyl diphosphate; Fig. 1), and include Smith-Lemli-Opitz syndrome,
desmosterolosis, lathosterolosis, hydrops–ectopic calcification–motheaten skeletal dysplasia,
X-linked dominant chondro-dysplasia punctata, congenital hemidysplasia with
ichthyosiform erythroderma and limb defects syndrome and sterol-C4-methyloxidase
deficiency [He et al., 2011; Porter and Herman, 2011]. The sole disorder of sterol
metabolism in the proximal pathway is represented by mevalonate kinase deficiency, a rare
disorder manifesting as two distinct syndromes: mevalonic aciduria and hyper-IgD
syndrome (HIDS) [Marcuzzi et al., 2012]. Mutations in the human MVK gene underlie both
diseases, and the neuropathology associated with mevalonic aciduria is generally absent in
patients with HIDS who manifest cyclic fever.
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The cholesterol pathway also generates a number of non-sterol isoprene compounds, the
most prominent represented by ubiquinone and the dolichols (Fig. 1). Isoprene (2-
methyl-1,3-butadiene), one of the most abundant molecular building blocks in nature, is
represented in the proximal pathway of cholesterol biosynthesis in the form of isopentenyl
phosphate (IPP; Fig. 1). Condensation of IPP with an additional activated isoprene,
dimethylallyl diphosphate, yields geranyl diphosphate (Fig. 1), which is further metabolized
to farnesyl diphosphate and eventually ubiquinone and the dolichols. The latter are
structurally similar, yet diverse, long-chain unsaturated intermediates that culminate in a free
alcohol moiety. This alcohol may undergo biological activation to produce both mono-and
di-phosphate species, the latter conjugating with various carbohydrates (glucose, galactose,
and mannose). Activated dolichol sugars serve as the carbohydrate donor to growing
oligosaccharide chains of post-translation-ally modified proteins (glycoproteins) and lipids
(glycolipids). These post-translational modifications encompass N-linked glycosylation (N =
the nitrogen side-group of the amino acids asparagine or arginine), O-linked glycosylation
(O = the oxygen in the alcohol side groups of serine, threonine or tyrosine) and C-linked
glycosylation (C = a carbon in the side chain of tryptophan). Once the sugar is donated, the
dolichol carrier is recycled for further intracellular reactions [Eklund and Freeze, 2006;
Freeze, 2007].
In the last decade, seven autosomal-recessively inherited disorders in the metabolism of the
dolichols have been described. All lead to hypoglycosylated target proteins, which allows
for the identification of these disorders in the diagnostic laboratory. Based upon this finding,
these disorders have been identified as congenital disorders of glycosylation (CDG) [Freeze,
2002; Freeze and Aebi, 2005; Denecke and Kranz, 2009]. In the current overview, we
highlight the common clinical features of and the approach to the diagnosis of these
disorders, which are unique in bridging the pathways of sterol biosynthesis with the
processes of molecular glycosylation (Table I).
DISORDERS IN THE SYNTHESIS OF DOLICHOLS
Dehydrodolichyl Diphosphate Synthase (DHDDS) Deficiency
DHDDS catalyzes the initial step in the synthesis of the dolichols and promotes chain
elongation to generate the poly-prenyl backbone. DHDDS is highly expressed in the
photoreceptor layer of the eye, highlighting the cardinal phenotypic feature of ocular
abnormalities associated with this disorder. For most patients, ocular symptoms reportedly
commence in the second decade of life with compromised night-vision followed by
progressive loss of peripheral vision with preservation of a central reading zone. DHDDS
gene mutations associate with retinitis pigmentosa (RP) type 59, which has only been
reported in the Ashkenazi Jewish population comprising 20 patients from 15 unrelated
families [Zelinger et al., 2011]. Three affected siblings in a single family manifested loss of
night and peripheral vision in their teens. Electroretinography, evaluating retinal cell
responses in these three patients, showed a complete absence of cellular response with
standard stimuli.
Homozygosity mapping identified a DHDDS gene variant on chromosome 1 (c.124A > G;
Lys42Glu). The variant was not identified in 109 additional Ashkenazi Jewish patients with
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RP, 20 Ashkenazi Jewish patients with other retinal disorders, or 70 Caucasian patients
(non-Ashkenazi Jewish) with retinal degeneration. The altered amino acid resides
proximally to the farnesyl-diphosphate binding site of the DHDDS protein (Fig. 1), which is
predicted to result in significant reduction of the dolichol phosphate pool required for
glycosylation of rod photoreceptor proteins. The same mutation was also identified in an
Ashkenazi Jewish family with an affected sibship employing whole exome sequencing
[Züchner et al., 2011]. These authors documented the pathogenicity of this variant
employing gene inactivation with morpholinos in the zebra fish homologue, replicating the
ocular anomalies observed in patients.
Steroid 5-α-Reductase 3 (SRD5A3) Deficiency
SRD5A3 encodes a protein belonging to both the steroid 5-α reductase and the polyprenol
reductase protein families that generate dolichols from polyprenols and is highly expressed
in brain tissue, retina, and heart. SRD5A3 deficiency was originally described in 12 patients
from nine families, predominantly consanguineous, presenting between 6 months and 12
years of age with comparable features. Ocular features in the predominantly female patients
included nystagmus, colobomas (retinal, iris, or chorioretinal), optic nerve hypoplasia or
atrophy, cataracts, glaucoma, and/or micro-ophthalmia (Fig. 2). Three patients had
congenital heart defects including an atrial septal defect, transposition of the great vessels
and a pulmonary valve defect. The differential diagnosis of coloboma, heart anomaly,
choanal atresia, retardation, genital and ear anomalies syndrome was ruled out by molecular
studies. Additional features in affected probands included severe intellectual disability,
cerebellar vermis atrophy, ataxia, transient microcytic anemia, liver dysfunction with
coagulopathy, feeding problems, ichthyosis, spasticity, movement disorders and stereotypic
movements [Morava et al., 2010]. Subsequently, a single affected male from a non-
consanguineous family was reported with the same disorder [Kasapkara et al., 2012].
Extended laboratory studies in these patients revealed an elevation of plasma polyprenols
detected on mass spectrometry. Homozygosity mapping identified seven mutations,
primarily missense, in the original 12 patients [Morava et al., 2010]. SRD5A3 deficiency
was previously described as Kahrizi syndrome in a large cohort of German patients, all of
whom manifested a homozygous mutation, but without confirmation of the underlying
plasma polyprenol accumulation [Kahrizi et al., 2011]. Thus, Kahrizi syndrome and
SRD5A3 deficiency are considered allelic disorders.
Dolichol Kinase (DK1) Deficiency
DK1 encodes a protein involved in the formation of dolichol mannose, essential for C-linked
mannosylation, N- and O-linked glycosylation, and the biosynthesis of
glycophosphatidylinositol (GPI) anchors in subcellular organelles such as the endoplasmic
reticulum (ER) [Chen et al., 1998]. The fatty acids within the phosphatidylinositol moiety
function to anchor the protein undergoing post-translational modification to the cell
membrane [Puoti and Conzelmann, 1992]. As expected, DK1 deficiency results in
disruption of multiple glycosylation pathways and manifests severe pathology [Denecke and
Kranz, 2009; Cantagrel and Lefeber, 2011].
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DK1 deficiency was initially reported in four children from two consanguineous families
[Kranz et al., 2007]. Clinical manifestations included microcephaly, “parchment-like”
ichthyosis with loss of hair, eyebrows and eyelashes, intractable seizures, severe hypotonia
with elevated Creatine Kinase (CK), severe liver dysfunction, and progressive dilated
cardiomyopathy resulting in death within 1 year. Dolichol kinase activity measured in skin
fibroblasts was 5% or less of parallel controls [Kranz et al., 2007]. Subsequently, Lefeber
reported 11 patients (5–13 years of age) with progressive dilated cardiomyopathy, mild
hypotonia with elevated CK levels and persistent elevations of transaminases, and mild
coagulopathy [Lefeber et al., 2011]. Half of the probands had variable ichthyosis, and mild
intellectual disability was noted in three. None showed overt seizure activity. Three novel
DK1 missense mutations were identified, which resulted in an O-linked mannosylation
abnormality of the heart-specific α-dystroglycan subunit.
Kapusta et al. [2012] recently provided a 5-year follow-up of nine surviving DK1-deficient
patients. All pro-bands were reported to have a primary cardiac presentation without
seizures, dysmorphic features, ichthyosis or intellectual disability. All had a dilated
cardiomyopathy that led to life-threatening dysrhythmias, persistent transaminase elevations
with decreased Factors XI and ATIII, and microcytic anemia, and the ensuing neutropenia
and overwhelming infections resulted in two deaths. A homozygous missense mutation
(His408Asp) in the DK1 gene was detected in two families, and a homozygous Trp304Cys
mutation in a third family. Four children with mild dilated cardiomyopathy were treated
with digoxin, diuretics, beta-blockers, and ACE-inhibitors. Three underwent heart
transplant, one of whom died unexpectedly at 16 years of age, and two of whom were 1 and
5 years post-transplant. Skin abnormalities in this cohort were reported as sporadic, mild dry
skin [Kapusta et al., 2012].
DISORDERS IN THE UTILIZATION AND RECYCLING OF DOLICHOLS
The dolichyl-phosphate mannosyltransferase (DPM; dolichyl-phosphate-D-mannose: protein
O-D-mannosyltransferase) is a three-subunit (DPM 1–3) enzyme that donates D-mannose
during glycosylation reactions on the luminal side of the ER (Fig. 1). Under regulation by
DPM2, DPM1 lacks a carboxy-terminal transmembrane domain and a signal sequence.
DPM2 is multifunctional and is also found in the GPI complex. Enzymatically active DPM1
is cytosolic and anchored to subunits 2 and 3 in the ER membrane via a C-terminal peptide
of DPM3 [Kim et al., 2000; Maeda et al., 2000]. Because multiple glycosylation pathways
are interrupted, it is predicted that an absence of any DPM subunit would lead to
multisystem pathology.
DPM 1–3 Deficiencies
Four patients with DPM1 deficiency have been reported. The phenotype encompassed
acquired microcephaly, dysmorphic facial features, visual loss with optic atrophy, frontal
cortical atrophy and delayed myelination, intractable seizures, hypotonia with elevated CK,
and low ATIII (antithrombin) [Imbach et al., 2000; Kim et al., 2000; Ashida et al., 2006].
Three patients from two Italian families were recently reported with DPM2 mutations. One
of the families was consanguineous. The phenotype included acquired microcephaly, severe
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hypotonia associated with elevated CK, difficulty swallowing, and early-onset myoclonic
epilepsy and cerebellar hypoplasia [Barone et al., 2012]. One female patient also manifested
hepatomegaly with elevated transaminases and low ATIII. All probands had cortical visual
impairment without structural eye abnormalities, and one male was diagnosed with optic
atrophy. All succumbed to lethal infections by 3 years of age. A homozygous missense
mutation c.68A>G; p.Tyr23Cys was found in one family, while the remaining family
revealed compound heterozygosity for the same missense mutation and a splice site
mutation [Barone et al., 2012]. A single adult patient with DPM3 deficiency developed
acquired short stature, mild intellectual disability, and a phenotype suggestive of mild
muscular dystrophy. Despite persistently elevated CK levels, muscle biopsy at age 11 years
was non-diagnostic. At age 20 years, she developed a dilated cardiomyopathy, and 1 year
later she experienced a stroke-like event with normal coagulation studies, normal radiologic
and unremarkable ophthalmology evaluations. A repeat muscle biopsy performed at this
time demonstrated an α-dystroglycan O-linked mannosylation defect. DPM activity
measured in muscle was 30% of controls. Sequencing of the DPM subunit genes revealed a
DPM3 mutation resulting in a Leu85Ser substitution in a highly conserved position of a
hydrophobic domain. Molecular modeling indicated that this mutation would negatively
impact DPM1 and DPM3 interactions, presumably destabilizing the DPM complex [Lefeber
et al., 2009].
Mannose-P-Dolichol Utilization Defect 1 (MPDU1) Protein Deficiency
MPDU1 encodes an ER membrane protein required for utilization of dolichol mannose in
the synthesis of lipid-linked oligosaccharides and GPI anchors. MPDU1 appears to function
as a chaperone for trafficking of dolichol mannose and dolichol glucosamine within the ER
membrane [Schenk et al., 2001; Denecke et al., 2009; Surmacz and Swiezewska, 2011].
MPDU1 deficiency was initially reported in three unrelated patients, two from
consanguineous families featuring early onset nystagmus and optic atrophy. Early visual
loss was confirmed by electroretinography. The phenotype included early-onset seizures (~5
months of age), ichthyosis, hypotonia with elevated CK, global developmental delay, failure
to thrive and recurrent vomiting. Brain MRI revealed generalized atrophy. One patient died
from presumed seizure-related apnea [Schenk et al., 2001]. Several missense mutations were
identified that appear to reduce mannosylation to some degree.
LABORATORY EVALUATION
Although regarded as rare, disorders altering the synthesis and/or utilization of the dolichols
may be underdiagnosed since routine characterization of transferrin glycosylation by
isoelectric focusing (IEF) or liquid chromatography methods may lack the sensitivity and
specificity required for their detection [Jaeken et al., 1994]. IEF of transferrin takes
advantage of the negatively charged sialic acid residues residing on the end of
oligosaccharide chains modifying glycosylated proteins. A type I pattern features
significantly increased disialo-transferrin and asialotransferrin species and concomitant
depletion of tetrasialo-transferrin, the predominant species in normal individuals, while less
sialiated forms, including asialotransferrin (zero sialic acids present), accumulate in patients
diagnosed with the so-called type II pattern, which is not seen in normal controls [Jaeken et
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al., 1994]. IEF of serum transferrin remains a prominent screening approach in the clinical
biochemical genetics laboratory. DHDDS, SRD5A3, DPM1, DPM2, DPM3, and DK1
defects demonstrate Type I patterns. One should note, however, that IEF analysis of serum
transferrin can be non-diagnostic for SRD5A3 deficiency in older individuals [Morava et al.,
2010; Cantagrel and Lefeber, 2011; Zelinger et al., 2011]. DPM1 and two deficiencies were
associated with an abnormal type I pattern, and abnormal lipid-linked oligosaccharides were
detected in fibroblasts. In DPM2 deficiency, due to the combined N- and O-linked
glycosylation defect, abnormal O-mannosylation in skeletal muscle was also confirmed
[Kim et al., 2000; Ashida et al., 2006]. Only subtle type I abnormalities were detected in
DPM3 deficiency, and a type I pattern was inconsistently present in MPDU1 deficiency
[Denecke et al., 2009; Lefeber et al., 2009; Surmacz and Swiezewska, 2011].
Based upon the preceding observations, specific plasma evaluations for N- and O-linked
glycans using liquid chromatography-tandem mass spectrometry (LC-MS/MS) or proteomic
methodology, in addition to molecular characterization, may ultimately be required to
identify all disorders involving the synthesis and utilization of the dolichols [He et al.,
2012]. The use of cultured skin fibroblasts for assessment of lipid-linked oligosaccharides
may also be beneficial, and for the disorders of O-mannosylation, specific immune-
histochemical tests on biopsied muscle may be required [He et al., 2012]. Because the DMP
complex affects multiple glycosylation/mannosylation pathways dependent upon dolichol
mannose availability, IEF analysis of serum trans-ferrin alone may be insufficient for
absolute identification [Ashida et al., 2006], and specific analyses of glycosylation in muscle
may be required.
SUMMARY
Based upon the clinical phenotypes described, we consider it prudent that patients presenting
with isolated RP, dilated cardiomyopathy, early onset seizure disorders not otherwise
explained, ichthyosis and/or a muscular dystrophy phenotype be evaluated for disorders
involving the synthesis and utilization of the dolichols, in addition to other disorders of
glycosylation. The multisystem pathology of these disorders, and the diverse pathways of
glycosylation that are interrupted, may require more sophisticated diagnostic protocols for
their identification, and thus we recommend referral of appropriate samples to specialist
laboratories with expertise in their identification to insure the most rapid and accurate
diagnosis.
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Figure 1.
Interrelationships between cholesterol biosynthesis and molecular glycosylation in the endoplasmic reticulum that is bridged via
the dolichols. The sites of the defects reported in this review are shown in red, including: dehydrodolichyl diphosphate synthase
(DHDDS) deficiency; steroid 5-α-reductase (SRD5A3) deficiency; dolichol kinase (DK1) deficiency; dolichyl-phosphate
mannosyl-transferase (DMP) complex deficiency (including defects in subunits DMP 1, 2, and 3); and mannose-P-dolichol
utilization defect 1 (MPDU1) protein deficiency. Additional abbreviations: CoA, coenzyme A; PP, pyrophosphate, or
diphosphate; GPI, glycophosphati-dylinositol. Not all steps in each pathway are shown.
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Figure 2.
(with permission from family). A: Facial features of SRD5A3-deficient patient at age 4 months. Note midfacial hypoplasia,
strabismus, and epicanthal folds. Absence of fixation was associated with glaucoma (and severely decreased visual function). B:
Sagittal MRI revealing generalized cerebral atrophy and vermis atrophy at the age of 2 years. C: Ichthyosis of the medial and
lateral borders of the palm and fingers, associated with extremely dry, thick skin with minimal scaling.
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TABLE I
Inherited Defects in the Synthesis and Recycling of the Dolichols
Disorder CDG nomenclature Chromosome localization Major organs involved
DHDDS deficiency DHDDS-CDG 1p36.11 Eye, skin, bone
SRD5A3 deficiency CDG-Iq 4q12 Brain, eye, heart, blood, GI, skin, bone
DK1 deficiency CDG-Im 9q34.11 Brain, muscle, heart, blood, GI, skin, bone
DPM1 deficiency CDG-Ie 20q13.13 Eye, brain, muscle, blood
DPM2 deficiency DPM2-CDG 9q34.13 Brain, muscle, GI
DPM3 deficiency CDG-Io 1q22 Brain, muscle, heart
MPDU1 deficiency CDG-If 17p13.1-p12 Brain, muscle, eye, GI, skin, bone
See text for disorder abbreviations. Additional abbreviations: CDG, congenital disorder of glycosylation; GI, gastrointestinal.
Am J Med Genet C Semin Med Genet. Author manuscript; available in PMC 2014 April 22.
